iiinova — where your digital self keeps evolving

Reposted by Sylvain Simon

Kate Markey @kate-fisher.bsky.social · 16/06/2026

Looking for a new postdoc to join my lab at the Fred Hutch in Seattle. Keen to find someone excited to dive into the mechanisms underlying microbial control of immune system recovery after transplant and immunotherapy! careers-fhcrc.icims.com/jobs/31336/p...

careers-fhcrc.icims.com

Fred Hutchinson Cancer Center

Fred Hutch is dedicated to the elimination of cancer and related diseases as causes of human suffering and death.

013

Sylvain Simon @sylvainsimon.bsky.social · 25/11/2025

We are hiring! We have a postdoc position opened @fredhutch.org to join our team to design next gen cellular therapies for cancer. Heavy focus on T cell signaling and understanding how synthetic receptors instruct T cells to fight cancer.

1119

Reposted by Sylvain Simon

Paul Thomas @pgtimmune.bsky.social · 24/11/2025

Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @markyarchoan.bsky.social & @pogorely.bsky.social www.nature.com/articles/s41...

nature.com

TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing - Nature Methods

TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.

43413

Reposted by Sylvain Simon

Waggoner Lab @labwaggoner.bsky.social · 24/10/2025

Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapy @natcancer.nature.com www.nature.com/articles/s43...

0105

Sylvain Simon @sylvainsimon.bsky.social · 10/10/2025

Excited to announce that I’ve recently transitioned into an Assistant Professor role in the Division of Translational Science and Therapeutics @Fred Hutch.

151

Reposted by Sylvain Simon

Laura Hartmann @lmhartmann.bsky.social · 23/09/2025

Check out one of our latest stories about combining our non viral knock-in strategy with integrases for an efficient, targeted integration of transgenes >8kb in human T cells! ‘One-pot’ PASTA: programmable and site specific transgene addition - all in just one reaction 🫕

062

Reposted by Sylvain Simon

Waggoner Lab @labwaggoner.bsky.social · 17/04/2025

Modulating AP-1 enables CAR-T cells to establish an intratumoral PD-1+ Tcf1+ stem-like reservoir and overcomes resistance to PD-1 axis blockade www.biorxiv.org/content/10.1...

041

Reposted by Sylvain Simon

bioRxiv Immunology @biorxiv-immuno.bsky.social · 15/04/2025

Modulating AP-1 enables CAR-T cells to establish an intratumoral PD-1+Tcf1+ stem-like reservoir and overcomes resistance to PD-1 axis blockade www.biorxiv.org/content/10.1101/202…

011

Sylvain Simon @sylvainsimon.bsky.social · 17/03/2025

Exciting news! Our latest manuscript is out! Really happy to report on the development of synthetic chimeric TCRs with enhanced antigen sensitivity and capable of bispecificity to successfully overcome tumor heterogeneity in pre-clinical models. Check it out: rdcu.be/edRwJ

rdcu.be

Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy

Nature Cancer - Simon, Bugos and colleagues report the design and characterization of monospecific and bispecific synthetic chimeric T cell receptors, conferring increased antigen sensitivity and...

1317

Reposted by Sylvain Simon

Rebecca D. Burdine, PhD @rburdine1.bsky.social · 11/02/2025

Make sure you, your trainees, and anyone else who might listen to you understands what "indirects" actually are, how they are established, and what Universities contribute. H/T @rodallab.bsky.social Please share widely! www.youtube.com/watch?v=yxTD...

youtube.com

Facilities and Administrative (F&A) Costs Explainer

YouTube video by Association of American Universities

6151113